Watch for enrollment updates and interim data from the Phase 3 MAPKeeper 301 trial, which will be the pivotal readout. The dual-mechanism narrative (tumor reduction + cachexia preservation) differentiates atebimetinib from standard MEK inhibitors, but confirmatory Phase 3 data are needed.
Price Chart
Executive Summary
Immuneering presented exploratory Phase 2a data at AACR Pancreatic Cancer 2026 showing that pancreatic cancer patients on atebimetinib + mGnP were twice as likely to maintain stable or increasing weight vs a benchmark study, and weight-stable patients had significantly longer overall survival (HR=3.13; p=0.049). The data support a dual mechanism of tumor volume reduction and body mass preservation, but are exploratory/post-hoc from a single-arm study (n=23 evaluable for weight trajectory). The Phase 3 MAPKeeper 301 trial is actively enrolling.
Key Facts
- Atebimetinib + mGnP patients were approximately two-fold more likely to have stable/increasing weight vs a published benchmark study (Fuller S, et al, JNCI, 2025).
- Patients with stable/increased weight at 3 months had significantly longer overall survival vs those who lost weight (HR=3.13; p=0.049).
- Median overall survival not reached in weight-stable group after median follow-up of 15.2 months.
- 66% of patients with low baseline FAACT-ACS scores (≤37) achieved ≥4-point improvement on this patient-reported outcome.
- Overall survival was comparable between patients with ≥30% SLD reduction and those with 0-30% SLD reduction, suggesting tumor reduction presence matters more than depth.
- Phase 3 MAPKeeper 301 trial (NCT07562152) is actively enrolling first-line pancreatic cancer patients.
Financial Impact
No financial figures provided; data are exploratory from a single-arm Phase 2a study. The Phase 3 trial is ongoing and no revenue or cost estimates are stated.
Risk Factors
- Data are exploratory, post-hoc, and from a single-arm Phase 2a study with small sample size (n=23 evaluable for weight trajectory).
- Phase 3 trial may fail to replicate these findings in a randomized, blinded setting.
- Cachexia benefit is based on patient-reported outcomes and weight trajectory, which are secondary/exploratory endpoints.
- Competing therapies in first-line pancreatic cancer (e.g., NALIRIFOX, modified FOLFIRINOX) may set a high bar for efficacy.
- Immuneering has no approved products and relies on successful Phase 3 readout and regulatory approval.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369791 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+1 | — | — |
Oct 2, 2026 24d ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.73 (−8.35%) |
Sep 28, 2026 28d ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.73 (−10.34%) |
Aug 26, 2026 8w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.73 (−28.41%) |
Aug 5, 2026 11w ago | 8-K | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Aug 5, 2026 11w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.73 (−9.47%) |
Jun 1, 2026 20w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.73 (−12.85%) |
May 15, 2026 23w ago | Press Release | $5.16 $4.87 | ▼ −5.62% | ▼ −5.56% | $3.73 (−27.71%) |
Apr 21, 2026 26w ago | Press Release | $5.89 $6.13 | ▲ +4.07% | ▲ +4.47% | $3.73 (−36.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers